|1.||Venot, Corinne: 2 articles (12/2010 - 09/2009)|
|2.||Lazar, Vladimir: 1 article (05/2013)|
|3.||Tolcher, Anthony W: 1 article (05/2013)|
|4.||Ozoux, Marie-Laure: 1 article (05/2013)|
|5.||Mery-Mignard, Dominique: 1 article (05/2013)|
|6.||Soria, Jean Charles: 1 article (05/2013)|
|7.||Deslandes, Antoine: 1 article (05/2013)|
|8.||Massard, Christophe: 1 article (05/2013)|
|9.||Soria, J-C: 1 article (03/2013)|
|10.||Bahleda, R: 1 article (03/2013)|
|1.||Lung Neoplasms (Lung Cancer)
08/01/2011 - "Moreover, inhibition of IGF-IR signaling by AVE1642 reduced IGF-I-induced VEGF production by NSCLC cells as well as the migratory capacity of HUVEC cells challenged with conditioned media from lung cancer cells previously exposed to IGF-I. The above results suggest that inhibition of IGF-IR signaling by AVE1642 enhances the efficacy of chemotherapy and modulates VEGF and angiogenesis in NSCLC. "
03/01/2013 - "This study assessed the safety, pharmacokinetics (PK), and tolerability of humanized IGF-1R antibody AVE1642 with other cancer treatments. "
12/01/2010 - "The human IGF-1R antagonistic monoclonal antibody EM164 (murine AVE1642) has shown activity in adult cancers and is being evaluated in patients with advanced malignancies. "
01/14/2010 - "EM164 and AVE1642 did not affect primary tumor growth of MDA-435A/LCC6 cells but inhibited metastasis of these cells. "
01/14/2010 - "To establish a clinically applicable approach to inhibition of metastasis by targeting IGF1R, we examined the effect of an inhibitory antibody against IGF1R, EM164 and its humanized version, AVE1642, on metastasis of cancer cells. "
03/01/2013 - "Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors."
|4.||Sarcoma (Soft Tissue Sarcoma)
12/01/2010 - "Our results demonstrate the potential of the anti-IGF-1R antibody alone and in combination with alkylating agents and support the therapeutic development of the AVE1642 for aggressive neuroblastoma."
12/01/2010 - "Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma."
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|2.||Conditioned Culture Media
|3.||Insulin-Like Growth Factor I (IGF-1)
|5.||Somatomedin Receptors (Somatomedin Receptor)
|7.||erlotinib (CP 358,774)
|1.||Drug Therapy (Chemotherapy)